A B S T R A C T A simple venous thrombosis model in rabbits was used for the quantitative evaluation of the thrombolytic effect of human extrinsic (tissue-type) plasminogen activator as compared with urokinase.
35% for 1-d-old clots, 30% for 3-d-old clots, and 50% for 7-d-old clots. The thrombolytic activity of urokinase was more than five times lower than that of extrinsic plasminogen activator: Infusion of 500,000 IU resulted in -40% lysis of fresh clots and 25% of 1-3- d-old clots, while 7-d-old clots appeared to have become resistent to urokinase. Local infusion resulted in a 5-10 times higher thrombolytic effect of both extrinsic plasminogen activator and urokinase.
Thrombolysis with extrinsic plasminogen activator was not associated with systemic activation of the fibrinolytic system as evidenced by unaltered plasma levels of fibrinogen, plasminogen, and a2-antiplasmin.
Systemic infusion of urokinase resulted in significant thrombolysis only at doses that were associated with disseminated plasminogen activation. Local infusion of urokinase required a 5-10-fold higher dose than extrinsic plasminogen activator to obtain a similar degree of thrombolysis, which also occurred in the absence of systemic activation of the fibrinolytic system.
It is concluded that the extent of thrombolysis by extrinsic plasminogen activator is mainly determined by the dose of activator and its delivery in the vicinity of the thrombus and much less by the age of the thrombus or the molecular form of the activator. Extrinsic plasminogen activator appears to be superior to urokinase because of its higher (5-10-fold) specific thrombolytic activity and the absence of systemic activation of the fibrinolytic system, which results in defibrinogenation and a bleeding tendency.
INTRODUCTION Extrinsic (tissue-type) plasminogen activator (EPA)' is a trypsinlike serine protease that may be isolated from the vessel wall (1) , from tissues (2-4), or from the culture fluid of a human melanoma cell culture (5) . It may be obtained either as a single-chain glycoprotein with 72,000M, or a two-chain disulfidebonded proteolytic derivative (5, 6) .
EPA, highly purified from the culture fluid of a human melanoma cell line (5) , has been shown to specifically activate plasminogen in the presence of fibrin (7, 8) and to be a more specific and more potent thrombolytic agent than urokinase in artificial systems in vitro (9) and in experimental animal models in vivo (10, 11) . The first experiments in humans have confirmed that infusion of EPA may result in thrombolysis without causing hemostatic breakdown and bleeding (12) . All these findings suggest that EPA may provide a new thrombolytic agent with higher specificity and less side effects than those currently in use.
In Blomback and Blomback (13) and labeled with 125I according to McFarlane (14) . Human thrombin was purified as described by Fenton et Fig. 1 .
The procedure to form a thrombotic venous occlusion (referred to as a clot) was as follows. Approximately [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Ml of '2RI-labeled human fibrinogen (containing -500,000 cpm) was aspirated in a 1.0-ml syringe followed by a volume of fresh rabbit blood corresponding to the measured volume of the isolated vein segment. The segment was then emptied by withdrawal of the saline through the side branch catheter, and 0.1 ml thrombin (100 NIH U/ml) was quickly injected, followed at once by the volume of blood containing the radioactive fibrinogen. Injection of air bubbles was avoided. Cotton swabs were then placed over the vessel to absorb FIGURE 1 Schematic representation of the surgical procedure used to produce a jugular vein thrombosis in rabbits.
Thrombolysis with Extrinsic Plasminogen Activator t369 blood leaking from the vein segment. In all instances, the clot formed quickly and was allowed to age for 30 min before both vessel clamps were removed. A blood sample was drawn immediately after removal of the vessel clamps to measure the radioactivity in the blood. The cotton swabs were removed for radioisotope counting and the amount of radioactivity delivered to the clot was calculated by subtracting the swab losses, the radioactivity remaining in the syringe, and the total blood radioactivity (assuming a blood volume of 60 ml/kg body weight) from the original amount of radioactivity in the syringe.
In the acute experiments with fresh thrombi, the urine bladder was catheterized and a 21-g butterfly needle was introduced in the contralateral marginal ear vein for infusion of the thrombolytic agents, which was started immediately. The bladder was emptied every hour, the urine volume was measured, and an aliquot was taken for radioisotope count Intravenous infusion of EPA, urokinase, or solvent (0.3 M NaCl containing 0.01% Tween 80) was carried out by using a constant rate infusion pump. The infusions. were given systemically through the contralateral marginal ear vein as a bolus injection of 2 ml (10% of the total volume) followed by an infusion of 18 ml over 4 h. Alternatively, the agents were given through a cathether introduced via the ipsilateral marginal ear vein into the immediate vicinity of the clot as a continuous infusion of 20 ml over 4 h. 6 h after the start of the infusion, the thrombosed segment of the jugular vein was removed after careful suturing of both ends and the remaining radioactive material was measured. The extent of thrombolysis was calculated as the difference between the radioactivity originally incorporated in the clot and the radioactivity in the vein segment, and expressed as percentage of the original radioactivity. The amount of radioactivity incorporated in the clot varied somewhat from one preparation of labeled fibrinogen to the other and with the age of the preparation. Thus, in the experiments with systemic infusions the isotope content of the clot was 198,000±19,000 cpm(mean±SEM) in the control groups (n = 22), 250,000±22,000 cpm in the groups receiving 100,000 IU of EPA (n = 28), and 263,000±3,200 cpm in the groups receiving 500,000 IU of urokinase (n = 14). In the experiments with local infusions these values were 335,000±34,000 cpm for the controls (n = 14), 295,000±25,000 cpm for the groups infused with 20,000 IU of EPA (n = 20), and 322,000±38,000 cpm for the groups infused with 100,000 IU of urokinase (n = 13). Activatorinduced thrombolysis (AIL) was calculated as the difference between the means of the percentage thrombolysis in a given activator-infused group (A) and its control group infused with solvent (C), divided by the difference between the total radioactivity in the clot (100%) and the mean of the percentage thrombolysis in the control group; thus, AIL = A -C/100 -C.
An isotope recovery balance was made by addition of the radioactivity in the recovered thrombus and in the blood at the end of the experiment (multiplied by three to correct for extravascular distribution) and was expressed as percentage of the original radioactivity in the clot. Urinary radioactivity was only measured in the experiments with fresh thrombi. It amounted to 20% in experiments with extensive clot lysis. In experiments with aged clots, quantitative urine collections were not performed. Thyroidal uptake of radioiodide or accumulation of labeled material in the lungs was found to be negligible.
2-ml blood samples were drawn into trisodium citrate (final concentration 0.011 M) and 1-ml samples into a mixture of 20 NIH U of thrombin and 250 U of aprotinin (Trasylol, Bayer, Leverkusen, West Germany) after removal of the vessel clamps and before the start of the infusion and at hourly intervals for 6 h. These plasma samples were used for measurements of radioactivity, fibrinogen (16), a2-antiplasmin (17) , fibrinogen degradation products (18) , and activated partial thromboplastin times (19) . Plasminogen was measured with the chromogenic substrate S-2251 (20) after activation for 10 min at 370C with 1,000 IU of urokinase/ 5 ,l plasma of which the plasmin inhibitors were first neutralized by acidification (21) . EPA was measured with a twosite immunoradiometric assay (22) .
The activated partial thromboplastin time before anticoagulation was 29±0.5 s (mean±SEM, n = 58), before the start of the thrombolytic experiments (i.e., 14 h after the last injection of 500 IU s.c. of heparin/kg body weight) it was 38±2.0 s (n = 80), and at the end of the experiments (i.e., 6 h after the heparin injection given at the beginning of the experiment) it was 55±3.2 s (n = 98). These (23) .
RESULTS
The extent of thrombolysis and the isotope recovery balance are shown in Tables I and II. In the control groups infused with solvent (systemically and/or locally), the average degree of thrombolysis was 5.6±1.4% (n = 5) after 6 h, 14 .5±1.7% (n = 10) after 30 h, 16 .0±1.5% (n = 11) after 78 h, and 48.1±2.7% (n = 10) after 174 h. Extension of the clot was not observed in the experiments with fresh clots but occurred Local infusion of one-or two-chain EPA in rabbits with clots aged for 1 or 3 d, resulted in a much higher degree of thrombolysis than that obtained by systemic infusion (Table II) . Thus, 20,000 IU given locally produced 64% lysis in 1-or 3-d-old clots, whereas 100,000 IU systemically yielded 44% thrombolysis. Likewise, 100,000 IU of urokinase locally resulted in a degree of thrombolysis similar to that obtained with 500,000 IU systemically.
Local infusion of 5,000 IU of EPA or 20,000 IU of urokinase did not result in a significant increment of spontaneous thrombolysis, suggesting that these fibrinolytic substances have to be infused above a certain threshold rate. Local infusion of 20,000 IU of EPA still produced extensive thrombolysis of clots aged for 7 d, whereas 100,000 IU of urokinase did not, confirming that 7-d-old clots are resistant to urokinase but still susceptible to EPA.
The AIL obtained with local infusion of 20,000 IU EPA was 63, 53, and 49% for clots aged for 1, 3, or 7 d, respectively, as compared with 20, 20, and 5%, respectively, with 100,000 IU of urokinase. These results indicate that the amount of activator required for thrombolysis is 5 to 10 times lower when given in local infusion as compared with systemic infusion.
The isotope recovery balances in the animals with local infusion (Table II) were comparable with those in the groups in which a similar degree of thrombolysis was obtained by systemic infusion.
The changes in the blood radioactivity during thrombolysis are summarized in Fig. 2 . After restoration of the blood flow, the radioactivity in the blood rose to -5% of the injected radioactivity, probably due to washing out of nonclotted labeled fibrinogen and to a lesser extent of free radioactivity. In the experiments with fresh thrombi (Fig. 2 a) , the blood radioactivity thereafter slowly declined in the control group and in the low-dose urokinase group (not shown) to about 50% of the initial value after 6 h. Systemic infusion of 20,000 IU of EPA resulted in a delayed decrease of the blood radioactivity. With 50,000 IU of EPA, the blood radioactivity rose by 25%, with 500,000 IU of urokinase by 75%, and with 100,000 IU of EPA by 400%. In all experiments with systemic infusion taken together the blood radioactivity did not change significantly in the control groups, but rose 2.5-fold after infusion of 500,000 IU of urokinase and 3.5-fold after infusion of 100,000 IU of EPA (Fig. 2 b) . Local infusion of 100,000 IU of urokinase produced a 2.5-fold increase of the blood radioactivity, whereas 20,000 IU of EPA produced a nearly 20-fold increase (Fig. 2 c) . Local infusion of 5P100 IU of EPA or 20,000 IU of urokinase did not produce a rise in the blood radioactivity. These findings confirm the higher specific thrombolytic activity of EPA as compared with urokinase.
The changes in the concentration of EPA in the blood are summarized in Fig. 3 ng/ml (n = 56). These findings indicate that the concentration of EPA in the blood is proportional to the rate of its infusion and that a constant steady-state concentration is obtained with a constant infusion rate. Fig. 4 presents the evolution of the most relevant hemostatic parameters in blood during and 2 h after the infusion. The fibrinogen level remained essentially unchanged in the control groups and the groups infused with 100,000 IU of EPA (Fig. 4 a) and only very small amounts of fibrinogen degradation products were generated in these groups (Fig. 4 b) . Infusion of 500,000 IU of urokinase, however, was associated with partial defibrinogenation evidenced by a decrease of the plasma fibrinogen level to 65% and the generation of fibrinogen degradation products up to a concentration equivalent to 10% of the plasma fibrinogen. Infusion of EPA or urokinase at the concentrations used in the other experimental groups did not produce measurable changes in the plasma levels of fibrinogen or fibrinogen degradation products. In line with these observations, infusion of 500,000 IU of urokinase provoked extensive systemic activation of the fibrinolytic system with a drop of the plasminogen level to -55% of the preinfusion value (Fig. 4 c) and of Ca2-antiplasmin to -40% (Fig. 4 d) . No evidence for systemic activation of the fibrinolytic system was observed in the other experimental groups.
DISCUSSION
The present study was undertaken to further investigate the thrombolytic properties of EPA in vivo and to evaluate some of the factors that determine the sensitivity of a thrombus to lysis. We have previously studied the thrombolytic effect of EPA in rabbits with an experimental pulmonary embolus (10) and in dogs with experimental femoral vein thrombosis (11) . In the former model, only very limited thrombolysis was obtained. In retrospect, this appeared to be due mostly to very limited accessibility to the clot and not to poor reactivity of the rabbits' fibrinolytic system (24) . The femoral vein thrombosis model in dogs yielded higher degrees of thrombolysis but this model is too expensive in terms of experimental animals, surgical equipment, and amounts of thrombolytic agents required to apply it on a larger scale. In order to circumvent some of these problems, we have developed a jugular vein thrombosis model in rabbits that can be studied in a normal laboratory environment and in which the extent of thrombolysis can be accurately quantitated. Our model is similar to a vena cava inferior thrombosis model recently described (25) The present results confirm and extend the conclusions of our two earlier studies that EPA is a thrombolytic agent with a specific activity, which is an order of magnitude greater than that of urokinase. In addition the present study shows again and in more detail that EPA can induce extensive thrombolysis without disseminated activation and consumption of the fibrinolytic system. Some additional findings may be important for the development of therapeutic regimens with EPA in man. Firstly, it appears that the one-and the two-chain forms of activator have very similar thrombolytic properties. This finding is in agreement with their similar kinetic properties (8) but at variance with the borderline-significant difference found in the dog femoral vein thrombosis model (11) . Secondly, it appears that in vivo aging of a clot has relatively little influence on its susceptibility to lysis by EPA in contrast to that with urokinase infusion. A third important conclusion of the present study is that the efficacy of the thrombolytic agents (both EPA and urokinase) is much higher when they are delivered into the immediate vicinity of the thrombus. Local infusion of 20,000 IU of EPA resulted in a higher degree of thrombolysis than systemic infusion of 100,000 IU. For urokinase the higher efficacy of local vs. systemic infusion was also evident although somewhat less marked.
The effect of increasing doses of EPA and urokinase was investigated in rabbits with fresh clots. Infusion of increasing amounts of EPA yielded increasing degrees of thrombolysis, but the dose response appeared not to be linear both for EPA and for urokinase.
The steady-state concentration of EPA in the blood was found to be directly proportional to the rate of infusion and was maintained at a constant level throughout the infusion period (measured half-way and at the end). We These considerations can probably be extrapolated to patients in the following way. The t1/2 of EPA in man has been estimated to be 10-15 min, corresponding to a clearance rate of 7% of the plasma pool per min. For a body weight of 70 kg and a plasma volume of 35 ml/kg this corresponds to a clearance of 175 ml plasma/min. Thus, to maintain a steady-state EPA level of 1 IU/ml, an infusion rate of 250,000 IU/24 h should be maintained. This is in reasonable agreement with actual levels of EPA measured in a few patients after infusion of EPA (unpublished observations).
The levels of EPA in blood required to obtain significant thrombolysis in 4 h are, however, >1 IU/ml. This level is much higher than the normal basic level of -0.2 IU/ml in man and comparable with the peak level, which is transiently obtained following exhaustive physical exercise or venous occlusion (22) . This may explain why the physiological dissolution of a thrombus in vivo in man, which fortunately occurs spontaneously in the majority of cases, is a time-consuming process. From the present experiments we cannot extrapolate to which extent a moderate increase of the EPA level in blood for prolonged periods of time may affect thrombus dissolution in man. In two selected cases systemic infusion of 5-7.5 mg (450,000-675,000 IU) EPA over 24 
